ArticleCancer chemotherapy and pharmacology2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOPN-2853 (formerly PLX2853, now dubbed zavabresib) is a potent, oral inhibitor of all four members of the bromodomain and extraterminal (BET) proteins, involved in epigenetic regulation across multiple cancers. This study aimed to determine the recommended Phase 2 dose (RP2D) of OPN-2853 and collect safety, pharmacokinetic and pharmacodynamic data in adults with advanced relapsed/refractory solid tumors or non-Hodgkin lymphoma (NHL).
methodsThis was a first-in-human, open-label, Phase 1b study. Primary endpoints included RP2D, pharmacokinetics and safety. Secondary and exploratory endpoints were efficacy and pharmacodynamics.
resultsForty-nine patients were enrolled. The RP2D was determined at 80 mg oral once daily (QD). The most common adverse events were nausea (n = 17 [24.7%], all < Grade 3) and fatigue (n = 12 [24.5%], n = 3 Grade 3). No OPN-2853-related deaths occurred. Three patients (6.1%) experienced dose-limiting toxicities: Grade 4 thrombocytopenia at 120 mg QD [n = 2] and a Cycle 1 dose reduction (Grade 3 fatigue with Grade 2 cheilitis and nausea [n = 1]). OPN-2853 has a short half-life (< 3 h). For pharmacodynamic response, gene expression changes in whole blood RNA-seq analysis were observed for up to 9 h. Of the 36 patients (73.4%) with at least one post-baseline assessment, 1 patient (2.8%) achieved a complete response with 18-month progression-free survival (PFS) and 1 patient (2.8%) achieved a partial response (PFS of 5.2 months). Another patient (2.8%) achieved an unconfirmed PR.
conclusionOPN-2853 was well tolerated at the RP2D in patients with advanced solid tumors and NHL, with modest clinical activity including two confirmed objective responses.
Indexed as
Identifiers
41787121What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.